Sodium Glucose Co-Transporter 2 (SGLT2) Inhibition with Canagliflozin in Type 2 Diabetes Mellitus

E-ISSN： 1875-6182|11|3|203-206

ISSN： 1871-5257

Source： Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Cardiovascular & Hematological Agents), Vol.11, Iss.3, 2013-09, pp. : 203-206

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Review of Sodium Glucose Co-transporter 2 Inhibitors Canagliflozin, Dapagliflozin and Empagliflozin

Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Cardiovascular & Hematological Agents), Vol. 13, Iss. 2, 2015-08 ,pp. : 105-112

Bentham Science Publishers

Access to resources Recommend Favorite

Editorial: Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes?

Current Vascular Pharmacology, Vol. 14, Iss. 6, 2016-10 ,pp. : 494-497

Bentham Science Publishers

Access to resources Recommend Favorite

Canagliflozin for the treatment of adults with Type 2 diabetes

By Aschner Pablo J

Diabetes Management, Vol. 3, Iss. 4, 2013-07 ,pp. : 343-350

Future Medicine

Access to resources Recommend Favorite

Alterations of Glucose Metabolism in Type 2 Diabetes Mellitus. An Overview

By Bonadonna Riccardo C.

Reviews in Endocrine and Metabolic Disorders, Vol. 5, Iss. 2, 2004-05 ,pp. : 89-97

Springer Publishing Company

Access to resources Recommend Favorite

Pancreatic &bgr;-cell Glucose Toxicity in Type 2 Diabetes Mellitus

Current Diabetes Reviews, Vol. 11, Iss. 1, 2015-03 ,pp. : 2-6

Bentham Science Publishers

Access to resources Recommend Favorite